![]() | |
Clinical data | |
---|---|
Other names | DWP16001 |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C24H27ClO6 |
Molar mass | 446.92 g·mol−1 |
3D model (JSmol) | |
| |
|
Enavogliflozin (DWP16001/GCC5694A) is a selective SLC5A2 and SGLT2 inhibitor developed to treat diabetes and obesity. [1] [2] [3] [4] [5] It was developed by GC Pharma [6] [7] and Daewoong Pharmaceutical. [7]
Enavogliflozin has been approved for clinical use in South Korea, [7] and Ecuador, [8] and applied for approval in Brazil, Mexico, Peru, and Colombia. [8]